{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T15:33:21Z","timestamp":1783784001872,"version":"3.55.0"},"reference-count":59,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T00:00:00Z","timestamp":1775088000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>\n                      The aim of this study was to compare and rank the efficacy and safety of four final oocyte maturation trigger strategies\u2014human chorionic gonadotropin (hCG), gonadotropin-releasing hormone agonist (GnRHa), dual, and double trigger\u2014in predicted high responders undergoing\n                      <jats:italic>in vitro<\/jats:italic>\n                      fertilization (IVF) with GnRH antagonist protocols, using a network meta-analysis (NMA) approach.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A systematic search of MEDLINE, EMBASE, CENTRAL, clinical trial registries, and the Cochrane Database of Systematic Reviews was conducted through December 2024. Eligible studies were randomized controlled trials (RCTs) including high responders, defined by elevated antral follicle count, anti-M\u00fcllerian hormone, or estradiol levels. Studies using GnRHa triggers followed by fresh embryo transfer were included only if intensive luteal phase support was provided. Oocyte donation cycles, quasi-randomized designs, and trials lacking outcome data were excluded. Data extraction and risk of bias assessment were independently conducted by two reviewers. Study integrity was evaluated using the TRACT checklist. NMA was performed in STATA (v16), and treatment ranking was based on Surface Under the Cumulative Ranking curve (SUCRA).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Seven high-quality RCTs comprising 632 women were included. There were no significant differences in the number of oocytes retrieved between GnRHa and hCG triggers (mean difference [MD] 1.08, 95% CI \u20131.06 to 3.22), dual and hCG (MD 0.61, 95% CI \u20131.53 to 2.74), or GnRHa and dual (MD 1.08, 95% CI \u20131.06 to 3.22). Similarly, there were no significant differences in mature oocyte yield, clinical pregnancy rate (CPR), or miscarriage rate across comparisons. However, GnRHa trigger significantly reduced the risk of moderate to severe ovarian hyperstimulation syndrome (OHSS) compared with hCG (RR 0.23, 95% CI 0.07\u20130.82). There were no significant differences in OHSS risk between dual and hCG (RR 0.28, 95% CI 0.05\u20131.64) or between GnRHa and dual (RR 0.28, 95% CI 0.05\u20131.64).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>GnRHa, hCG, and dual triggers demonstrate similar efficacy in terms of oocyte yield, maturity, and clinical pregnancy rates in predicted high responders. The GnRHa trigger, however, offers a superior safety profile by significantly lowering the risk of OHSS. Larger multicenter RCTs are required to evaluate live birth outcomes and the potential role of the double trigger in this population.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Systematic review registration<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link>https:\/\/www.crd.york.ac.uk\/prospero\/<\/jats:ext-link>\n                      , identifier CRD42022351423.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fendo.2026.1669781","type":"journal-article","created":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T04:18:35Z","timestamp":1775103515000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Oocyte maturation triggering in high responders in IVF treatment: a systematic review and network meta-analysis"],"prefix":"10.3389","volume":"17","author":[{"given":"Yusuf","family":"Beebeejaun","sequence":"first","affiliation":[{"name":"Department of Women\u2019s and Children\u2019s Health, Faculty of Life Sciences and Medicine, King\u2019s College London","place":["London, United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy","family":"Copeland","sequence":"additional","affiliation":[{"name":"Department of Clinical Neuroscience Karolinska Institute","place":["Solna, Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James M. N.","family":"Duffy","sequence":"additional","affiliation":[{"name":"Centre for Reproductive Medicine, St Bartholomew\u2019s Hospital","place":["London, United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ippokratis","family":"Sarris","sequence":"additional","affiliation":[{"name":"King\u2019s Fertility, Fetal Medicine Research Institute","place":["London, United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marian","family":"Showell","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, University of Auckland","place":["Auckland, New Zealand"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sesh K.","family":"Sunkara","sequence":"additional","affiliation":[{"name":"Department of Women\u2019s and Children\u2019s Health, Faculty of Life Sciences and Medicine, King\u2019s College London","place":["London, United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,4,2]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1210\/er.2017-00236","article-title":"Novel concepts for inducing final oocyte maturation in in vitro fertilization treatment","volume":"39","author":"Abbara","year":"2018","journal-title":"Endocrine Rev"},{"key":"B2","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.fertnstert.2013.09.033","article-title":"Impact of final oocyte maturation using gonadotropin-releasing hormone agonist triggering and different luteal support protocols on endometrial gene expression","volume":"101","author":"Bermejo","year":"2014","journal-title":"Fertility Sterility"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.654028","article-title":"Mechanisms of oocyte maturation and related epigenetic regulation","volume":"9","author":"He","year":"2021","journal-title":"Front Cell Dev Biol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.humrep.a019329","article-title":"Recovery of corpus luteum function after prolonged deprivation from gonadotrophin stimulation","volume":"11","author":"Weissman","year":"1996","journal-title":"Hum Reprod"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.humrep.a136151","article-title":"Endocrinology: Follicle stimulating hormone alone supports follicle growth and oocyte development in gonadotrophin-releasing hormone antagonist-treated monkeys","volume":"10","author":"Zelinski-Wooten","year":"1995","journal-title":"Hum Reproduction"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2025.1556732","article-title":"Dual triggering for final oocyte maturation. A narrative review","volume":"16","author":"Riob\u00f3","year":"2025","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1210\/jcem.75.2.1639951","article-title":"Administration of human luteinizing hormone (hLH) to macaques after follicular development: further titration of LH surge requirements for ovulatory changes in primate follicles","volume":"75","author":"Zelinski-Wooten","year":"1992","journal-title":"J Clin Endocrinol Metab"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/S0015-0282(03)00173-0","article-title":"Use of recombinant human chorionic gonadotropin in ovulation induction","volume":"79","author":"Ludwig","year":"2003","journal-title":"Fertility Sterility"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-9258(18)36031-9","article-title":"Structures of N-glycosidic carbohydrate units of human chorionic gonadotropin","volume":"254","author":"Kessler","year":"1979","journal-title":"J Biol Chem"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1210\/jcem-57-4-792","article-title":"Hormonal dynamics at midcycle: a reevaluation","volume":"57","author":"Hoff","year":"1983","journal-title":"J Clin Endocrinol Metab"},{"key":"B11","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1186\/s13048-015-0187-6","article-title":"Triggering final follicular maturation--hCG, GnRH-agonist or both, when and to whom","volume":"8","author":"Orvieto","year":"2015","journal-title":"J Ovarian Res"},{"key":"B12","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/S1472-6483(10)60615-3","article-title":"Substituting HCG with GnRH agonist to trigger final follicular maturation--a retrospective comparison of three different ovarian stimulation protocols","volume":"13","author":"Orvieto","year":"2006","journal-title":"Reprod BioMed Online"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1093\/humupd\/3.3.255","article-title":"The role of vascular endothelial growth factor and interleukins in the pathogenesis of severe ovarian hyperstimulation syndrome","volume":"3","author":"Rizk","year":"1997","journal-title":"Hum Reprod Update"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1210\/jcem-71-4-918","article-title":"Use of gonadotropin-releasing hormone agonist to trigger follicular maturation for in vitro fertilization","volume":"71","author":"Gonen","year":"1990","journal-title":"J Clin Endocrinol Metab"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1093\/humrep\/15.9.1965","article-title":"Use of a single bolus of GnRH agonist triptorelin to trigger ovulation after GnRH antagonist ganirelix treatment in women undergoing ovarian stimulation for assisted reproduction, with special reference to the prevention of ovarian hyperstimulation syndrome: preliminary report: short communication","volume":"15","author":"Itskovitz-Eldor","year":"2000","journal-title":"Hum Reprod"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.fertnstert.2003.05.032","article-title":"Luteolysis induced by a gonadotropin-releasing hormone agonist is the key to prevention of ovarian hyperstimulation syndrome","volume":"81","author":"Kol","year":"2004","journal-title":"Fertility sterility"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1210\/jcem.87.2.8197","article-title":"Endocrine profiles after triggering of final oocyte maturation with GnRH agonist after cotreatment with the GnRH antagonist ganirelix during ovarian hyperstimulation for in vitro fertilization","volume":"87","author":"Fauser","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"B18","article-title":"Timing of HCG administration for ovulation triggering in GnRH antagonist cycles A randomized controlled trial","volume":"15","author":"Kolibianakis","year":"2003","journal-title":"Human Fertility"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1093\/humrep\/deh765","article-title":"GnRH agonist (buserelin) or hCG for ovulation induction in GnRH antagonist IVF\/ICSI cycles: a prospective randomized study","volume":"20","author":"Humaidan","year":"2005","journal-title":"Hum Reprod"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.fertnstert.2008.12.015","article-title":"Gonadotropin-releasing hormone agonist or human chorionic gonadotropin for final oocyte maturation in an oocyte donor program","volume":"93","author":"Erb","year":"2010","journal-title":"Fertil Steril"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1093\/humupd\/dmi045","article-title":"GnRH agonist for triggering final oocyte maturation in the GnRH antagonist ovarian hyperstimulation protocol: a systematic review and meta-analysis","volume":"12","author":"Griesinger","year":"2006","journal-title":"Hum Reprod Update"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1093\/humrep\/dei475","article-title":"VEGF and TNFalpha levels after triggering oocyte maturation with GnRH agonist compared with HCG in women with polycystic ovaries undergoing IVF treatment: a prospective randomized trial","volume":"21","author":"Babayof","year":"2006","journal-title":"Hum Reprod"},{"key":"B23","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.fertnstert.2007.02.002","article-title":"The use of gonadotropin-releasing hormone (GnRH) agonist to induce oocyte maturation after cotreatment with GnRH antagonist in high-risk patients undergoing in vitro fertilization prevents the risk of ovarian hyperstimulation syndrome: a prospective randomized controlled study","volume":"89","author":"Engmann","year":"2008","journal-title":"Fertil Steril"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/S1472-6483(10)60612-8","article-title":"Rescue of corpus luteum function with peri-ovulatory HCG supplementation in IVF\/ICSI GnRH antagonist cycles in which ovulation was triggered with a GnRH agonist: a pilot study","volume":"13","author":"Humaidan","year":"2006","journal-title":"Reprod BioMed Online"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.fertnstert.2008.12.042","article-title":"1,500 IU human chorionic gonadotropin administered at oocyte retrieval rescues the luteal phase when gonadotropin-releasing hormone agonist is used for ovulation induction: a prospective, randomized, controlled study","volume":"93","author":"Humaidan","year":"2010","journal-title":"Fertil Steril"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1093\/humrep\/dei150","article-title":"A lower ongoing pregnancy rate can be expected when GnRH agonist is used for triggering final oocyte maturation instead of HCG in patients undergoing IVF with GnRH antagonists","volume":"20","author":"Kolibianakis","year":"2005","journal-title":"Hum Reproduction"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD008046.pub4","article-title":"Gonadotropin-releasing hormone agonist versus HCG for oocyte triggering in antagonist-assisted reproductive technology","author":"Youssef","year":"2014","journal-title":"Cochrane Database Systematic Rev"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.fertnstert.2010.09.023","article-title":"Recombinant LH as luteal supplementation method after agonist triggering in IVF. A proof of concept study","volume":"95","author":"Papanikolaou","year":"2011","journal-title":"Fertil Steril"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.fertnstert.2011.03.109","article-title":"Comparison of \u201ctriggers\u201d using leuprolide acetate alone or in combination with low-dose human chorionic gonadotropin","volume":"95","author":"Shapiro","year":"2011","journal-title":"Fertility sterility"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.fertnstert.2007.06.030","article-title":"Gonadotropin-releasing hormone agonist combined with a reduced dose of human chorionic gonadotropin for final oocyte maturation in fresh autologous cycles of in vitro fertilization","volume":"90","author":"Shapiro","year":"2008","journal-title":"Fertil Steril"},{"key":"B31","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1186\/1757-2215-7-77","article-title":"Co-administration of GnRH-agonist and hCG for final oocyte maturation (double trigger) in patients with low number of oocytes retrieved per number of preovulatory follicles--a preliminary report","volume":"7","author":"Haas","year":"2014","journal-title":"J Ovarian Res"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/j.fertnstert.2010.09.023","article-title":"A novel method of luteal supplementation with recombinant luteinizing hormone when a gonadotropin-releasing hormone agonist is used instead of human chorionic gonadotropin for ovulation triggering: a randomized prospective proof of concept study","volume":"95","author":"Papanikolaou","year":"2011","journal-title":"Fertil Steril"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1080\/09513590.2019.1576621","article-title":"Does double trigger (GnRH-agonist\u2009+\u2009hCG) improve outcome in poor responders undergoing IVF-ET cycle? A pilot study","volume":"35","author":"Haas","year":"2019","journal-title":"Gynecol Endocrinol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.7326\/M14-2385","article-title":"The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations","volume":"162","author":"Hutton","year":"2015","journal-title":"Ann Intern Med"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1093\/humrep\/deh098","article-title":"Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS)","volume":"19","year":"2004","journal-title":"Hum Reprod"},{"key":"B36","doi-asserted-by":"publisher","first-page":"hoaa009","DOI":"10.1093\/hropen\/hoaa009","article-title":"ESHRE guideline: ovarian stimulation for IVF\/ICSI(\u2020)","volume":"2020","author":"Ata","year":"2020","journal-title":"Hum Reprod Open"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.29252\/ijrm.15.11.735","article-title":"Low-dose hCG as trigger day and 35 hr later have different ovarian hyperstimulation syndrome occurrence in females undergoing in vitro fertilization: An RCT","volume":"15","author":"Aghahosseini","year":"2017","journal-title":"Int J Reprod BioMed"},{"key":"B38","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s13048-019-0483-7","article-title":"Low dose human chorionic gonadotropin administration at the time of gonadotropin releasing-hormone agonist trigger versus 35\u2009h later in women at high risk of developing ovarian hyperstimulation syndrome - a prospective randomized double-blind clinical trial","volume":"12","author":"Engmann","year":"2019","journal-title":"J Ovarian Res"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/j.fertnstert.2015.01.034","article-title":"Luteal phase supplementation after gonadotropin-releasing hormone agonist trigger in fresh embryo transfer: the American versus European approaches","volume":"103","author":"Humaidan","year":"2015","journal-title":"Fertility Sterility"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1093\/humrep\/dev184","article-title":"Daily low-dose hCG stimulation during the luteal phase combined with GnRHa triggered IVF cycles without exogenous progesterone: a proof of concept trial","volume":"30","author":"Andersen","year":"2015","journal-title":"Hum Reprod"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1093\/humrep\/dey054","article-title":"Towards an optimal luteal support modality in agonist triggered cycles: a randomized clinical trial","volume":"33","author":"Elgindy","year":"2018","journal-title":"Hum Reprod"},{"key":"B42","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s41073-023-00130-8","article-title":"Checklist to assess Trustworthiness in RAndomised Controlled Trials (TRACT checklist): concept proposal and pilot","volume":"8","author":"Mol","year":"2023","journal-title":"Res Integr Peer Rev"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1003082","article-title":"CINeMA: An approach for assessing confidence in the results of a network meta-analysis","volume":"17","author":"Nikolakopoulou","year":"2020","journal-title":"PloS Med"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1093\/humrep\/deaa241","article-title":"Developing a core outcome set for future infertility research: an international consensus development study\u2020 \u2021","volume":"35","author":"Duffy","year":"2020","journal-title":"Hum Reproduction"},{"key":"B45","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.fertnstert.2020.11.012","article-title":"Developing a core outcome set for future infertility research: an international consensus development study \u2020 \u2021","volume":"115","author":"Duffy","year":"2021","journal-title":"Fertility Sterility"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1016\/j.fertnstert.2009.09.009","article-title":"International Committee for Monitoring Assisted Reproductive Technology (ICMART) and the World Health Organization (WHO) revised glossary of ART terminology, 2009\u2217","volume":"92","author":"Zegers-Hochschild","year":"2009","journal-title":"Fertility Sterility"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0076654","article-title":"Graphical tools for network meta-analysis in STATA","volume":"8","author":"Chaimani","year":"2013","journal-title":"PloS One"},{"key":"B48","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions","author":"Higgins","year":""},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1177\/1536867X1501500403","article-title":"Network meta-analysis","volume":"15","author":"White","year":"2015","journal-title":"Stata J"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1093\/aje\/kwab278","article-title":"Introducing the treatment hierarchy question in network meta-analysis","volume":"191","author":"Salanti","year":"2022","journal-title":"Am J Epidemiol"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1093\/humrep\/det249","article-title":"GnRHa trigger and individualized luteal phase hCG support according to ovarian response to stimulation: two prospective randomized controlled multi-centre studies in IVF patients","volume":"28","author":"Humaidan","year":"2013","journal-title":"Hum Reprod"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1016\/j.fertnstert.2019.04.034","article-title":"Independent serum markers of corpora lutea function after gonadotropin-releasing hormone agonist trigger and adjuvant low dose human chorionic gonadotropin in in vitro fertilization","volume":"112","author":"Kaye","year":"2019","journal-title":"Fertil Steril"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.4103\/0974-1208.192056","article-title":"Gonadotropin-releasing hormone agonist trigger is a better alternative than human chorionic gonadotropin in PCOS undergoing IVF cycles for an OHSS Free Clinic: A Randomized control trial","volume":"9","author":"Krishna","year":"2016","journal-title":"J Hum Reprod Sci"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.15296\/ijwhr.2022.20","article-title":"Comparison of Ovulation Triggering Outcomes by Standard Dose of hCG versus Declined hCG Dose With GnRH Agonist in Antagonist Cycles: A Randomized Clinical Trial","volume":"10","author":"Valipour","year":"2022","journal-title":"J Women\u2019s Health Reprod Sci"},{"key":"B55","article-title":"Dual triggering in antagonist ICSI cycles","volume-title":"Human Reproduction","author":"Yildiz","year":""},{"key":"B56","doi-asserted-by":"publisher","first-page":"9","DOI":"10.29252\/ijrm.16.1.9","article-title":"Fresh versus frozen embryo transfer after gonadotropin-releasing hormone agonist trigger in gonadotropin-releasing hormone antagonist cycles among high responder women: A randomized, multi-center study","volume":"16","author":"Aflatoonian","year":"2018","journal-title":"Int J Reprod BioMed"},{"key":"B57","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s13048-019-0483-7","article-title":"Low dose human chorionic gonadotropin administration at the time of gonadotropin releasing-hormone agonist trigger versus 35 h later in women at high risk of developing ovarian hyperstimulation syndrome - a prospective randomized double-blind clinical trial","volume":"12","author":"Engmann","year":"2019","journal-title":"J Ovarian Res"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1016\/j.fertnstert.2018.02.003","article-title":"Luteal phase support after gonadotropin-releasing hormone agonist triggering: does it still matter","volume":"109","author":"Benadiva","year":"2018","journal-title":"Fertility Sterility"},{"key":"B59","article-title":"Combined administration of gonadotropin-releasing hormone agonist with human chorionic gonadotropin for final oocyte maturation in GnRH antagonist cycles for in vitro fertilization","volume":"59","author":"Kim","year":"2014","journal-title":"J Reprod Med"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1669781\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T04:18:43Z","timestamp":1775103523000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1669781\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,2]]},"references-count":59,"alternative-id":["10.3389\/fendo.2026.1669781"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2026.1669781","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,2]]},"article-number":"1669781"}}